Sign in
Taking people in United StatesEarly phase 1

Ceftriaxone given in pulses for lingering symptoms after Lyme disease treatment

Tests ceftriaxone against placebo in adults with symptoms lasting after Lyme disease treatment.

Key facts

Who runs it
State University of New York - Upstate Medical University
Where
East Syracuse, United StatesSee the site
Trial code
Registry title
Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
Status
Recruiting
Phase
Early phase 1
People taking part
44 people, planned
Started
3 Feb 2025
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ceftriaxone (Rocephin®)
  • Dextrose 5% (D5W)
Record updated
19 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had Lyme disease and still have lasting or returning symptoms after finishing treatment (PTLDS). It tests ceftriaxone given about every 5 days against placebo.

Age
18 to 75 years
Sex
All sexes
Disease stage
A past well-defined or probable Lyme disease infection, and meeting the definition of PTLDS. Tiredness must get in the way of work, school or social life (FSS score of 4 or higher). Lyme symptoms present for no more than 10 years.
Earlier treatment
No Lyme antibiotics (doxycycline, amoxicillin, cefuroxime, azithromycin, ceftriaxone or penicillin) for at least 6 weeks before joining. No outside antibiotics during treatment.

Main reasons for not taking part

  • Pregnant or breastfeeding, or planning pregnancy during the about 45-day treatment period
  • Allergy or serious reaction to cephalosporin antibiotics, or severe allergic reaction to penicillins
  • Infection with HIV-1, hepatitis B or hepatitis C (people with well-controlled HIV on ART with CD4 count above 200 can join)
  • Bipolar disorder, schizophrenia, a mental health hospital stay in the past year, or raised suicide risk
  • Past Clostridium difficile infection, taking warfarin, or Lyme diagnosis based only on a positive IgM immunoblot

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Age 18 to 75 at the time of consent
  • Ability and willingness to sign informed consent
  • Available for the study period
  • Must have met the definition of a prior well-defined or probable Lyme disease infection, AND meet the definition of PTLDS
  • Provide consent for release of medical history records from primary care physician, college or university, urgent care or emergency room visit
  • Have a level of fatigue that interferes with their ability to function in their job, schooling, or other social/personal activities (FSS score of 4 or higher)
  • Subjects will need to have been off of antibiotics (those standard antibiotics used to target Lyme disease to include doxycycline, amoxicillin, cefuroxime, azithromycin, ceftriaxone or penicillin) for at least 6 weeks prior to study enrollment and be willing to remain off of any outside antibiotics during the duration of the treatment component of the study

Who cannot take part

  • Known concurrent rheumatologic or similar disease thought to interfere with study participation or confound results at the discretion of the investigator. These may include but are not limited to rheumatoid arthritis, systemic lupus erythematous, Sjogren's syndrome, scleroderma, psoriasis, fibromyalgia, chronic fatigue syndrome/myalgic encephalomyelitis, or obstructive sleep apnea
  • Hives, shortness of breath, swelling of the lips or throat, or hospitalization related to a previous treatment with a cephalosporin antibiotic, or severe allergic reaction to penicillins (e.g. anaphylaxis or severe rash with Stevens Johnson syndrome or similar)
  • 12. Participation (active or follow-up phase) or planned participation in another vaccine, drug, or medical device in the 4 weeks prior to this trial, within 5 times the elimination half-life, whichever is longer, or during the trial
  • Prior history of Clostridium difficile infection
  • Currently taking warfarin (Coumadin)
  • Patients with a diagnosis of Lyme disease based on only a positive Lyme IgM immunoblot
  • A history of cephalosporin allergy or significant intolerance
  • Diagnosis with Bipolar Disorder or Schizophrenia, hospitalization in the past year for a mental health disorder, or any other psychiatric condition (to include any finding of increased suicide risk as identified by a rating of moderate or high risk on the CSSRS assessment), which in the opinion of the investigator prevents the subject from participating in the study
  • Significant screening physical examination abnormalities or chronic medical condition that in the opinion of the investigator may impact subject safety
  • Blood tests confirming infection with human immunodeficiency virus- 1 (HIV-1), hepatitis C, hepatitis B (assessed by HbsAg) virus; Note: Subjects who have well controlled HIV, who are on ART with a CD4 count greater than 200 will be allowed to participate
  • Female: pregnant or lactating
  • Women who intend to become pregnant during the treatment study period (approximately 45 days)
  • Lyme related symptoms that have been present for greater than 10 years
  • Planned travel during the study period that would interfere with the ability to complete all study visits (this can be a temporary exclusion with plan to schedule enrollment during a window of time during which they could attend their study visits)
  • Unable to comply with study requirements
  • Clinician discretion

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • SUNY Upstate Medical University, Upstate Global Health InstituteEast Syracuse, United StatesContact: Keely TerrillionTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if an FDA approved drug, Ceftriaxone, given intermittently, can treat people between 18 and 75 years old with a history of Lyme disease, who are still experiencing persistent or returning symptoms after they have completed treatment. The main questions it aims to answer are:

Read full original descriptionShow less

* Will giving Ceftriaxone approximately every 5 days for 6 weeks be safe and well tolerated when compared to a group that receives placebo (a look-alike substance that contains no drug)? * Will giving Ceftriaxone improve symptoms?

Participants will be asked to do the following:

* Come to the clinic approximately every 5-6 days to receive an IV infusion of either the Ceftriaxone or placebo. * Answer questions about their level of tiredness, body pain, general health and physical ability, sleep, anxiety, depression and any suicidal thoughts. * Give blood so we can make sure your body is handling the drug okay or to help us learn more about how the drug is affecting the persistent Lyme disease symptoms.

The 2 groups in the trial

  • CeftriaxoneExisting treatment, for comparison

    Participants will receive IV infusion of 2g Ceftriaxone, approximately every 5 days for 6 weeks for a total of 9 treatments.

    Treatment: Ceftriaxone (Rocephin®)

  • PlaceboPlacebo, for comparison

    Participants will receive IV infusion of dextrose 5% in water, approximately every 5 days for 6 weeks for a total of 9 treatments

    Treatment: Dextrose 5% (D5W)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial of Pulse Dosed Ceftriaxone for Post-Treatment Lyme Disease
Plain-language title
Ceftriaxone given in pulses for lingering symptoms after Lyme disease treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06611111, who can take part
Record updated
19 March 2026